Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid

Slides:



Advertisements
Similar presentations
Donna A. Culton, Suzanne K. McCray, Moonhee Park, James C
Advertisements

TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid  Yale Liu, Lingling Peng, Liang Li, Chengfei Liu, Xiao Hu, Shengxiang Xiao,
Making the Most of In Vitro Tests to Diagnose Food Allergy
Emmanuel Contassot, Lars E. French 
Increasing the Complement of Therapeutic Options in Bullous Pemphigoid
The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis  Yosuke Kanno, En Shu,
Toll-Like Receptor-4 Deficiency Enhances Repair of UVR-Induced Cutaneous DNA Damage by Nucleotide Excision Repair Mechanism  Israr Ahmad, Eva Simanyi,
Expanding Our Understanding of Human Skin Aging
Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma
SATB1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas
Stem Cell Therapy for Epidermolysis Bullosa—Does It Work?
Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease  Monica G. Lawrence, MD, Judith A. Woodfolk, MBChB,
B-Cell-Directed Therapy for Inflammatory Skin Diseases
Michael L. Frisoli, John E. Harris 
Comparative Effectiveness Research
Takashi Hashimoto, Norito Ishii, Daisuke Tsuruta 
Clinical Snippets Journal of Investigative Dermatology
TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention  Karsten Mahnke, Alexander H. Enk  Journal.
Association of Serum B-Cell Activating Factor Level and Proportion of Memory and Transitional B Cells with Clinical Response after Rituximab Treatment.
Xiang Ding, Luis A. Diaz, Janet A. Fairley, George J. Giudice, Zhi Liu 
Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis  Huijie Yuan, Shengru Zhou, Zhicui Liu, Weiting Cong, Xiaochun Fei,
The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies  Anika Kasprick, Maike M. Holtsche,
Emmanuel Contassot, Lars E. French 
Erratum Journal of Investigative Dermatology
Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari 
Satoshi Nakamizo, Tetsuya Honda, Kenji Kabashima 
Clinical Snippets Journal of Investigative Dermatology
Research Techniques Made Simple: Cost-Effectiveness Analysis
John J. Zone, C. Anthony Egan, Ted B. Taylor 
An Unexpected Role for TRPV4 in Serotonin-Mediated Itch
Circulating Tumor Cells and Melanoma Progression
Biologics and biomarkers for asthma, urticaria, and nasal polyposis
Tamar Nijsten  Journal of Investigative Dermatology 
More Than Many: How to Manage the Most Frequent Cancer?
Taia T. Wang, Jeffrey V. Ravetch  Immunity 
Minutes of the Board of Directors Meeting
Cells to Surgery Quiz: June 2017
Journal of Investigative Dermatology
Cancer Stem Cells in Squamous Cell Carcinoma
IL-17 Takes Center Stage in Dermatophytosis
Clinical Snippets Journal of Investigative Dermatology
Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein 
Research Techniques Made Simple: Itch Measurement in Clinical Trials
Identification of a Potential Effector Function for IgE Autoantibodies in the Organ- Specific Autoimmune Disease Bullous Pemphigoid  Otobia G. Dimson,
Ryan P. Hobbs, Susan H. Smith, Spiro Getsios 
Journal of Investigative Dermatology
Journal of Investigative Dermatology 
TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid  Yale Liu, Lingling Peng, Liang Li, Chengfei Liu, Xiao Hu, Shengxiang Xiao,
Michael C. Velarde  Journal of Investigative Dermatology 
Society for Investigative Dermatology 2010 Meeting Minutes
Journal of Investigative Dermatology
Erratum Journal of Investigative Dermatology
Anti-Cytokine Therapies in Response to Systemic Infection
Research Snippets Journal of Investigative Dermatology
How Much Sun Protection Is Needed
Dagmar Simon, Luca Borradori, Hans-Uwe Simon 
BJD Editor’s Choice Journal of Investigative Dermatology
Repeated Topical Challenge with Chemical Antigen Elicits Sustained Dermatitis in NC/Nga Mice in Specific-Pathogen-Free Condition  Yoshiaki Tomimori, Yoshitaka.
Cells to Surgery Quiz: February 2019
The Thomsen-Friedenreich Antigen-Binding Lectin Jacalin Interacts with Desmoglein-1 and Abrogates the Pathogenicity of Pemphigus Foliaceus Autoantibodies.
Basophils and mast cells in renal injury
Journal of Investigative Dermatology
Journal of Investigative Dermatology
Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer’s Disease  Nina Kokkonen, Sanna-Kaisa.
Janet A. Fairley, Chang Ling Fu, George J. Giudice 
Conditional Autoantibodies in Urticaria Patients: A Unifying Hypothesis  Beda M. Stadler, Jana Pachlopnik, Monique Vogel, Michael Horn, Markus Dahinden,
Journal of Investigative Dermatology
Journal of Investigative Dermatology
Flor Evangelista, David A. Dasher, Luis A. Diaz, Phillip S
A Subset of Pemphigus Foliaceus Patients Exhibits Pathogenic Autoantibodies Against Both Desmoglein-1 and Desmoglein-3  Luis A. Arteaga, Philip S. Prisayanh,
Presentation transcript:

Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid Ning Li, Donna Culton, Luis A. Diaz, Zhi Liu  Journal of Investigative Dermatology  Volume 138, Issue 6, Pages 1249-1251 (June 2018) DOI: 10.1016/j.jid.2018.02.020 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Proposed modes of action of IVIG in BP. The mechanisms of IVIG as a therapeutic include the saturation of the IgG protective FcRn; the neutralization of autoantibodies by anti-idiotypic antibodies; the neutralization cytokines or modulation of cytokine production; the attenuation of complement-mediated tissue damage; the modulation of functions and expression of the IgG receptors FcγRs; and the modulation of effector functions of T, B, and dendritic cells. In mouse models of BP, IVIG are protective through the saturation of FcRn and anti-idiotypic antibodies to reduce circulating pathogenic IgG levels and by modulation of IL-6 and IL-10 production. BP, bullous pemphigoid; FcRn, neonatal FcR receptor; IVIG, intravenous Ig. Journal of Investigative Dermatology 2018 138, 1249-1251DOI: (10.1016/j.jid.2018.02.020) Copyright © 2018 The Authors Terms and Conditions